Ulcerative Colitis
1,156
137
189
569
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
203 trials with published results (18%)
Research Maturity
569 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
11.7%
135 terminated out of 1156 trials
80.8%
-5.8% vs benchmark
19%
218 trials in Phase 3/4
36%
203 of 569 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 569 completed trials
Clinical Trials (1156)
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
Early Changes in Inflammatory Indices and Healing in IBD
Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation
Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis
Evaluation of the SIMBA Capsule for Small Intestinal Dysbiosis
Alpha Lipoic Acid in Ulcerative Colitis
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
A Comprehensive Self-Management Intervention for Individuals With Inflammatory Bowel Disease
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Immune Regulation in Ulcerative Colitis or Crohn s Disease
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)